Daniel Kelsey named CEO of AHRA

The Association for Medical Imaging Management (AHRA) has appointed Daniel Kelsey, as the organization's new CEO, according to a Nov. 15 AHRA press release. Kelsey will lead AHRA’s team in expanding the organization's programs and membership base for the medical imaging professionals.  

“As a veteran of the healthcare association world, I’m very excited to join AHRA, the preeminent organization for imaging leaders, who set and live up to high standards for quality care and innovation,” Kelsey said in a prepared statement. “I look forward to upholding the AHRA’s strong priorities and financial soundness, while expanding its reach to increase the impact and awareness of the organization.” 

Having more than 20 years of business development and management experience, Kelsey was previously deputy CEO at the American Association of Clinical Endocrinologists. Prior to that, he served for 14 years at the Indiana State Medical Association, including eight years as the director of membership and practice advisory group.
 
“Dan’s strategic drive, distinguished career in the association management community and passion for membership make him the perfect choice to lead AHRA and help shape the strategic focus and advocacy efforts of the next phase of its development. We’re thrilled to welcome Dan aboard,” said AHRA President Bill Algee. 

""

A recent graduate from Dominican University (IL) with a bachelor’s in journalism, Melissa joined TriMed’s Chicago team in 2017 covering all aspects of health imaging. She’s a fan of singing and playing guitar, elephants, a good cup of tea, and her golden retriever Cooper.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.